Literature DB >> 19509152

GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer.

Debby M E I Hellebrekers1, Marjolein H F M Lentjes, Sandra M van den Bosch, Veerle Melotte, Kim A D Wouters, Kathleen L J Daenen, Kim M Smits, Yoshimitsu Akiyama, Yasuhito Yuasa, Silvia Sanduleanu, Carolina A J Khalid-de Bakker, Daisy Jonkers, Matty P Weijenberg, Joost Louwagie, Wim van Criekinge, Beatriz Carvalho, Gerrit A Meijer, Stephen B Baylin, James G Herman, Adriaan P de Bruïne, Manon van Engeland.   

Abstract

PURPOSE: The transcription factors GATA4 and GATA5 are involved in gastrointestinal development and are inactivated by promoter hypermethylation in colorectal cancer. Here, we evaluated GATA4/5 promoter methylation as potential biomarkers for noninvasive colorectal cancer detection, and investigated the role of GATA4/5 in colorectal cancer. EXPERIMENTAL
DESIGN: Promoter methylation of GATA4/5 was analyzed in colorectal tissue and fecal DNA from colorectal cancer patients and healthy controls using methylation-specific PCR. The potential function of GATA4/5 as tumor suppressors was studied by inducing GATA4/5 overexpression in human colorectal cancer cell lines.
RESULTS: GATA4/5 methylation was observed in 70% (63/90) and 79% (61/77) of colorectal carcinomas, respectively, and was independent of clinicopathologic features. Methylation frequencies in normal colon tissues from noncancerous controls were 6% (5 of 88, GATA4; P < 0.001) and 13% (13 of 100, GATA5; P < 0.001). GATA4/5 overexpression suppressed colony formation (P < 0.005), proliferation (P < 0.001), migration (P < 0.05), invasion (P < 0.05), and anchorage-independent growth (P < 0.0001) of colorectal cancer cells. Examination of GATA4 methylation in fecal DNA from two independent series of colorectal cancer patients and controls yielded a sensitivity of 71% [95% confidence interval (95% CI), 55-88%] and specificity of 84% (95% CI, 74-95%) for colorectal cancer detection in the training set, and a sensitivity of 51% (95% CI, 37-65%) and specificity of 93% (95% CI, 84-100%) in the validation set.
CONCLUSIONS: Methylation of GATA4/5 is a common and specific event in colorectal carcinomas, and GATA4/5 exhibit tumor suppressive effects in colorectal cancer cells in vitro. GATA4 methylation in fecal DNA may be of interest for colorectal cancer detection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19509152     DOI: 10.1158/1078-0432.CCR-09-0055

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  88 in total

1.  Upstream stimulatory factor 1 activates GATA5 expression through an E-box motif.

Authors:  Bohao Chen; Rona Hsu; Zhenping Li; Paul C Kogut; Qingxia Du; Kelly Rouser; Blanca Camoretti-Mercado; Julian Solway
Journal:  Biochem J       Date:  2012-08-15       Impact factor: 3.857

2.  GATA6 promotes colon cancer cell invasion by regulating urokinase plasminogen activator gene expression.

Authors:  Narasimhaswamy S Belaguli; Muhammad Aftab; Mohammed Rigi; Mao Zhang; Daniel Albo; David H Berger
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

3.  Loss of GATA5 expression due to gene promoter methylation induces growth and colony formation of hepatocellular carcinoma cells.

Authors:  Lei Xia; Yan Gong; Aiqun Zhang; Shouwang Cai; Qiang Zeng
Journal:  Oncol Lett       Date:  2015-11-25       Impact factor: 2.967

4.  Epigenetic and copy number variation analysis in retinoblastoma by MS-MLPA.

Authors:  Gabriella Livide; Maria Carmela Epistolato; Mariangela Amenduni; Vittoria Disciglio; Annabella Marozza; Maria Antonietta Mencarelli; Paolo Toti; Stefano Lazzi; Theodora Hadjistilianou; Sonia De Francesco; Alfonso D'Ambrosio; Alessandra Renieri; Francesca Ariani
Journal:  Pathol Oncol Res       Date:  2012-01-26       Impact factor: 3.201

5.  GATA transcription factors in vertebrates: evolutionary, structural and functional interplay.

Authors:  Yanyan Tang; Yunfei Wei; Wenwu He; Yongbo Wang; Jianing Zhong; Chao Qin
Journal:  Mol Genet Genomics       Date:  2013-12-25       Impact factor: 3.291

Review 6.  How does genome sequencing impact surgery?

Authors:  Marlies S Reimers; Charla C Engels; Peter J K Kuppen; Cornelis J H van de Velde; Gerrit J Liefers
Journal:  Nat Rev Clin Oncol       Date:  2014-06-24       Impact factor: 66.675

Review 7.  Advances in epigenetic biomarker research in colorectal cancer.

Authors:  Xi Wang; Ye-Ye Kuang; Xiao-Tong Hu
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

8.  Regulation of endoderm formation and left-right asymmetry by miR-92 during early zebrafish development.

Authors:  Nan Li; Chunyao Wei; Abigail F Olena; James G Patton
Journal:  Development       Date:  2011-03-29       Impact factor: 6.868

Review 9.  DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer.

Authors:  Yutaka Hashimoto; Timothy J Zumwalt; Ajay Goel
Journal:  Epigenomics       Date:  2016-04-22       Impact factor: 4.778

10.  Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution.

Authors:  Hongcang Gu; Christoph Bock; Tarjei S Mikkelsen; Natalie Jäger; Zachary D Smith; Eleni Tomazou; Andreas Gnirke; Eric S Lander; Alexander Meissner
Journal:  Nat Methods       Date:  2010-01-10       Impact factor: 28.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.